

## Report from the ASGT Ad Hoc Committee on Retroviral-mediated Gene Transfer to Hematopoietic Stem Cells

**Table 1: Published Retroviral Gene Transfer Studies in Non-Human Primates**

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Kantoff <i>et al.</i> , 1987)	Rhesus	4	BM MNCs	3 < 1 yr, 1 14 years	RV	Neo, ADA	None long-term	None
(Bodine <i>et al.</i> , 1990)	Rhesus	3	BM MNCs	1 year	RV (helper-contaminated)	Neo	< 1%	None
(Donahue <i>et al.</i> , 1992; Vanin <i>et al.</i> , 1994)	Rhesus	10	BM MNCs or CD34+ cells	6 animals not developing lymphoma followed 120 months (0.5-1% marking)	RV (helper-contaminated)	Neo	0-10%	3 T cell lymphomas (months 3-4)
(Van Beusechem <i>et al.</i> , 1992)	Rhesus	3	BM MNCs	< 1 yr	RV	ADA	< 1%	None
(Bodine <i>et al.</i> , 1993)	Rhesus	2	CD34+ BM, ablative TBI	96 months	RV	ADA	1%	None
(Van Beusechem <i>et al.</i> , 1993)	Rhesus	3	BM MNCs	13 months	RV	ADA	< 1%	None
van Besc 1994(Van Beusechem <i>et al.</i> , 1994)	Rhesus	2	CD34+, 11b-BM, ablative TBI	15 months	RV	ADA	< 1%	None

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Van Beusechem <i>et al.</i> , 1995)	Rhesus		CD34+ BM, ablative TBI		RV	ADA	< 1%	
(Xu <i>et al.</i> , 1995)	Rhesus	3	CD34+ BM, ablative TBI	96 months	RV	gluco-cerebrosidase	< 1%	None
(Dunbar <i>et al.</i> , 1996)	Rhesus	4	CD34+ BM or PBSC	12 months	RV	Neo	1%	None
(Donahue <i>et al.</i> , 1996)	Rhesus	3	CD34+/Thy1+ BM, ablative TBI	12 months	RV	gluco-cerebrosidase	< 1%	None
(Kaptein <i>et al.</i> , 1997)	Rhesus	2	BM, ablative TBI	36 months	RV	ADA	<1%	None
(Kiem <i>et al.</i> , 1997)	Baboon	4	CD34+ BM	6 months	RV	Neo	1%	None
(Bunnell <i>et al.</i> , 1997)	Rhesus	3	T cells	6 months	RV	Neo	Transient 10%, then < 0.1%	None
(Kiem <i>et al.</i> , 1998)	Baboon	5	CD34+ BM	up to 67 months	RV	Neo, AlkP	1-10%	None
(Tisdale <i>et al.</i> , 1998)	Rhesus	8	CD34+ PBSC, ablative TBI	3-60 months	RV	Neo	1-3% in 4 animals	None
(Donahue <i>et al.</i> , 1998)	Rhesus	3	T cells	6 months	RV	antisense tat/rev, Neo	0.2-2%	None
(Ierino <i>et al.</i> , 1999)	Baboon	5	BM MNCs	< 6 months	RV	swine MHC gene, Neo	< 1%	None

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Rosenzweig <i>et al.</i> , 1999)	Rhesus	6	CD34+ BM non-ablative TBI	12 months	RV	GFP	< 1%	1 animal with hemolytic anemia 20 wks post-transplant, responded to steroids, no increase in vector-containing cells
(Bunnell <i>et al.</i> , 1999)	Rhesus	5	CD34+ PBSC, or BM ablative TBI	12 months	RV	Neo	<1%	None
(Hanazono <i>et al.</i> , 1999)	Rhesus	4	T cells	12 months	RV	Neo and non-expressed Neo	< 1%	None
(Huhn <i>et al.</i> , 1999)	Rhesus	4	CD34+ PBSC	50-150 months	RV	Neo	1-2%	None
(An <i>et al.</i> , 2000)	Rhesus	4	CD34+ PBSC or BM, ablative TBI	56-60 months	LV	GFP	0.1-2%	None
(Andrews <i>et al.</i> , 2000)	Baboon	3	CD34+ or CD34- BM, allo cells	15 months	RV	Neo	< 1%	None
(Heim <i>et al.</i> , 2000)	Rhesus	10	T cells or CD34+ PBSC/ablative TBI	6-50 months	RV	Neo and non-expressed Neo	0.1-3%	None
(Wu <i>et al.</i> , 2000; Kim <i>et al.</i> , 2000; Schmidt <i>et al.</i> , 2002)	Rhesus	4	CD34+ PBSC/ablative TBI	40-60 months	RV	Neo	1-15%	None

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Donahue <i>et al.</i> , 2000)	Rhesus	5	CD34+ PBSC/ablative TBI	6-60 months	RV	GFP	3-5%	None
(Shi <i>et al.</i> , 2001)	Rhesus	3	CD34+ PBSC/ablative TBI		RV	Neo, G6PD	1-3%	None
(Sellers <i>et al.</i> , 2001)	Rhesus	2	CD34+ PBSC/ablative TBI	48 months	RV	Neo, MDR1	1-5%	None
(Kurre <i>et al.</i> , 2001)	Baboon	7	CD34+ BM	up to 3 years	RV	Neo, GFP	1-8%	None
(An <i>et al.</i> , 2001)	Rhesus	6	CD34+ PBSCs	40-44 months (GFP), 18-20 months (IL2RG)	LV	GFP (n=4) or human IL2RG (n=2)	0.5-5%	None
(Rosenzweig <i>et al.</i> , 2001)	Rhesus	4	CD34+ PBSC/non-ablative TBI	16-20 months	RV	CD24	up to 35% first 2-4 months, then < 1%	None
(Hanazono <i>et al.</i> , 2002b)	Cyno.	3	CD34+ BM	12-24 months	RV	GFP	< 1%	None
(Takatoku <i>et al.</i> , 2001)	Baboon	4	CD34+ PBSC/ablative TBI	36-42 months	RV	Neo	1-25%	None

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Kelly <i>et al.</i> , 2002)	Rhesus	6	CD34+ PBSC/ablative TBI	up to 40 months	RV	GFP	<1%-5%, one animal with oligoclonal marking only, up to 80% marking for 6 months, now only 1%	None
(Hanazono <i>et al.</i> , 2002a)	Rhesus	8	CD34+ BM	< 12 months	RV	GFP, non-expression neo, truncated G-CSFR/estrogen R chimera	0.5-1% with estrogen agonist treatment, 14 clones identified by inverse PCR	None
(Kluge <i>et al.</i> , 2002)	Rhesus	3	CD34+ PBSC/ablative TBI	20-30 months	RV	Neo	0.1-5%	None
(Kurre <i>et al.</i> , 2002)	Baboon	4	CD34+ BM	20 months	RV	GFP/YFP	2-6%	None
(Horn <i>et al.</i> , 2002a)	Baboon	4	CD34+ BM	30 months (1 animal), rest < 6 months	LV/RV	GFP/YFP	10% (all from LV, slow increase between 3-10 months)	None
(Kiem <i>et al.</i> , 2002)	Baboon	6	CD34+ BM	< 12 months	RV	GFP	<2%	None
(Horn <i>et al.</i> , 2002b)	Baboon	3	CD34+ BM	12 months	RV	GFP/YFP	10-30%	None

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Hematti <i>et al.</i> , 2003)	Rhesus	5	CD34+ PBSC or BM/ablative TBI		RV	Neo	None	None

**Table 2: Published Retroviral Gene Transfer Studies In Dogs*****A. Autologous Transplantation of Transduced Bone Marrow or Peripheral Blood Cells***

Reference	Number	Method or Cellular Target	Follow-up in publication	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Carter <i>et al.</i> , 1992)	9	21-day cultured marrow, ablative TBI	21 months	RV	Neo	< 1%	None
(Bienzle <i>et al.</i> , 1994)	18	21-day cultured marrow, no ablation before infusion	24 months	RV	Neo	CFU up to 20% ? PB < 1%	None
(Lutzko <i>et al.</i> , 1999a)	5	21-day cultured marrow, no ablation	36 months	RV	canine alpha-L-iduronidase	< 1%	None
Kiem	2	PBSC, MHCII+, 11 day culture, ablation	17 months	RV	Neo	< 1%	None
(Barquinero <i>et al.</i> , 1995)	19	Bone marrow or PBSC, no ablation (4), some ablation (12), complete ablation (3)	< 1 year	RV	Neo	< 1%	None
(Schuening <i>et al.</i> , 1991) Kiem 1996	5	Bone marrow, ablative TBI	63 months (1), 50 months (1), 24 months (3)	RV	Neo, ADA	<1%	None
(Kiem <i>et al.</i> , 1999)	4	CD34+ BM, ablative TBI	18 months	RV	Neo	Up to 10%	None

Reference	Number	Method or Cellular Target	Follow-up in publication	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Goerner <i>et al.</i> , 1999)	4	CD34+ BM, ablative TBI	< 1 year	RV	Neo	Up to 10-15%	None
(Goerner <i>et al.</i> , 2001)	3	CD34+ BM, ablative TBI	23 months	RV	GFP, Neo	Up to 10%	None
(Georges <i>et al.</i> , 2001)	8	Donor T cells, allo transplant	< 1 year	RV	GFP, Neo	Up to 7%	None
(Bruno <i>et al.</i> , 2001)	3	CD34+ BM, ablative TBI	12 months	RV	Neo	< 1%	None
{Neff, Horn, et al. 2002 4724 /id}	1	CD34+ BM, ablative TBI	6 months	RV	MGMT p140K mutant	pre-drug 15-20%, post-O6PG and BCNU 55-80%	None
(Neff <i>et al.</i> , 2002)	2	CD34+ BM, ablative TBI	12 months	RV	conditional mpl with dimerization domain	1-2%, transient increases to 10% with dimerizer rx	None, except plt decrease on dimerizer
(Whitwam <i>et al.</i> , 1998),(Licht <i>et al.</i> , 2002)	8	Bone marrow, 200 rads TBI one dog taxol 23 months	16 months, 3 dogs 23 months, one dog 33 months	RV	IL2Rgamma, Neo, MDR1	up to 25% but transient	None
(Ting <i>et al.</i> , 2002)	3	Bone marrow, no ablation	< 6 months	RV	IL2RG	10-20% short-term	died of SCID

***B. Direct Injection of Vector or Transduced Cells Into Pre-Immune Fetuses or Neonates***

<b>Reference</b>	<b>Number</b>	<b>Method</b>	<b>Follow-up</b>	<b>Vector</b>	<b>Trangene (s)</b>	<b>Stable Gene Transfer Levels</b>	<b>Reported AEs</b>
(Omori <i>et al.</i> , 1999)	6	Injection of transduced human BM	< 12 months	RV	Neo	< 1% then none	None
(Lutzko <i>et al.</i> , 1999b)	12	Vector Injection	< 12 months	RV	Canine alpha-L-iduronidase or Neo	< 1%	None other than disease (MPS I) progression
(Meertens <i>et al.</i> , 2002)	7	Vector Injection	< 12 months	RV	Canine alpha-L-iduronidase	< 1%	None other than disease (MPS I) progression
(Xu <i>et al.</i> , 2002)	5	Vector Injection	6 months	RV	beta-glucuronidase	< 1%	None
(Ponder <i>et al.</i> , 2002)	7	Vector Injection	14-17 months	RV	beta-glucuronidase	< 1%	None

**Table 3: Published Retroviral Gene Transfer Studies in Sheep**

Reference	Species	Number	Method	Follow-up	Vector	Trangene (s)	Stable Gene Transfer Levels	Reported AEs
(Kantoff <i>et al.</i> , 1989)	Sheep	10	transduced human BM cells IP	24 months	RV	Neo	< 1%	None
(Tran <i>et al.</i> , 2001)	Sheep	14	vector IP injection (no human cells)	40 months (9 animals)	RV	B-gal, Neo		None0-6.5%
(Porada <i>et al.</i> , 2002)	sheep	7-primary 4 secondary 4 tertiary	vector IP injection after transplant of human BM cells		RV	Neo, B-gal	10-20%	None
(Tsai <i>et al.</i> , 2002)	sheep	6	transduced human X-SCID CD34+ BM IP		RV	IL2R	All human T cells +	None
(Lucas <i>et al.</i> , 2002)	sheep	4	transduced human CD34+ BM IP	6 months	RV	B-gal	> 10%	None

**Table 4: Published Retroviral Gene Transfer Studies in Other Large Animal Models**

Reference	Species	Number	Method	Follow-up	Vector	Transgene (s)	Stable Gene Transfer Levels	Reported A.E.s
(Lothrop, Jr. <i>et al.</i> , 1991)	Cat	4	BM MNCs	< 1 year	RV	Neo	< 1%	3 animals diabetes day 90
(Nelson <i>et al.</i> , 1997)	Rabbit	5	Direct BM injection of vector	up to 20 months	RV	Neo	< 1%	None
(Josephson, Sabo & Abkowitz, 2000)	Cat	1	BM MNCs	14 months	RV	Neo	< 1%	None
(Sonntag <i>et al.</i> , 2001)	Minature Swine	5	BM MNCs	12 months	RV	MHC class II	< 1%	None

## Reference List for Published Studies

- AN,D.S., KUNG,S.K., BONIFACINO,A., WERSTO,R.P., METZGER,M.E., AGRICOLA,B.A., MAO,S.H., CHEN,I.S. & DONAHUE,R.E. (2001). Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. *J. Virol.* **75**, 3547-3555.
- AN,D.S., WERSTO,R.P., AGRICOLA,B.A., METZGER,M., LU,S., AMADO,R.G., CHEN,I.S.Y. & DONAHUE,R.E. (2000). Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34+ cells. *J. Virol.* **74**, 1286-1295.
- ANDREWS,R.G., PETERSON,L.J., MORRIS,J., POTTER,J., HEYWARD,S., GOUGH,M., BRYANT,E. & KIEM,H. (2000). Differential engraftment of genetically modified CD34(+) and CD34(-) hematopoietic cell subsets in lethally irradiated baboons. *Exp. Hematol.* **28**, 508-518.
- BARQUINERO,J., KIEM,H.P., VON KALLE,C., DAROVSKY,B., GOEHLE,S., GRAHAM,T., SEIDEL,K., STORB,R. & SCHUENING,F.G. (1995). Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. *Blood* **85**, 1195-1201.
- BIENZLE,D., ABRAMS-OGG,A.C.G., KRUTH,S.A., ACKLAND-SNOW,J., CATER,R.F., DICK,J.E., JACOBS,R.M., KAMEL-REID,S. & DUBÉ,I.D. (1994). Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 350-354.
- BODINE,D.M., MCDONAGH,K.T., BRANDT,S.J., NEY,P.A., AGRICOLA,B., BYRNE,E. & NIENHUIS,A.W. (1990). Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 3738-3742.
- BODINE,D.M., MORITZ,T., DONAHUE,R.E., LUSKEY,B.D., KESSLER,S.W., MARTIN,D.I., ORKIN,S.H., NIENHUIS,A.W. & WILLIAMS,D.A. (1993). Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. *Blood* **82**, 1975-1980.
- BRUNO,B., GOERNER,M.A., NASH,R.A., STORB,R., KIEM,H.P. & MCSWEENEY,P.A. (2001). Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis. *Biol. Blood Marrow Transplant.* **7**, 543-551.
- BUNNELL,B.A., KLUGE,K.A., LEE-LIN,S.Q., BYRNE,E.R., ORLIC,D., METZGER,M.E., AGRICOLA,B.A., WERSTO,R.P., BODINE,D.M., MORGAN,R.A. & DONAHUE,R.E. (1999). Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells. *Gene Ther.* **6**, 48-56.
- BUNNELL,B.A., METZGER,M., BYRNE,E., MORGAN,R.A. & DONAHUE,R.E. (1997). Efficient in vivo marking of primary CD4+ T lymphocytes in non-human primates using a gibbon ape leukemia virus-derived retroviral vector. *Blood* **89**, 1987-1995.
- CARTER,R.F., ABRAMS-OGG,A.C.G., DICK,J.E., KRUTH,S.A., VALLI,V.E., KAMEL-REID,S. & DUBE,I.D. (1992). Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. *Blood* **79**, 356-364.
- DONAHUE,R.E., BUNNELL,B.A., ZINK,M.C., METZGER,M.E., WERSTO,R.P., KIRBY,M.R., UNANGST,T., CLEMENTS,J.E. & MORGAN,R.A. (1998). Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. *Nat. Med.* **4**, 181-186.
- DONAHUE,R.E., BYRNE,E.R., THOMAS,T.E., KIRBY,M.R., AGRICOLA,B.A., SELLERS,S.E., GAUDERNACK,G., KARLSSON,S. & LANSDORP,P.M. (1996). Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells. *Blood* **88**, 4166-4172.
- DONAHUE,R.E., KESSLER,S.W., BODINE,D., MCDONAGH,K., DUNBAR,C., GOODMAN,S., AGRICOLA,B., BYRNE,E., RAFFELD,M., MOEN,R. & NIENHUIS,A.W. (1992). Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. *J. Exp. Med.* **176**, 1125-1135.
- DONAHUE,R.E., WERSTO,R.P., ALLAY,J.A., AGRICOLA,B.A., METZGER,M.E., NIENHUIS,A.W., PERSONS,D.A., NIENHUIS,A.W. & SORRENTINO,B.P. (2000). High levels of lymphoid expression of

enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells. *Blood* **95**, 445-452.

DUNBAR,C.E., SEIDEL,N.E., DOREN,S., SELLERS,S., CLINE,A.P., METZGER,M.E., AGRICOLA,B.A., DONAHUE,R.E. & BODINE,D.M. (1996). Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 11871-11876.

GEORGES,G.E., STORB,R., BRUNO,B., BRODIE,S.J., THOMPSON,J.D., TARANOVA,A.G., ZAUCHA,J.M., LITTLE,M.T., ZELLMER,E., MOORE,P.F., GOOLEY,T., SALE,G., KIEM,H.P., SANDMAIER,B.M., LYONS,R.M. & NASH,R.A. (2001). Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. *Blood* **98**, 3447-3455.

GOERNER,M., BRUNO,B., MCSWEENEY,P.A., BURON,G., STORB,R. & KIEM,H.P. (1999). The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs. *Blood* **94**, 2287-2292.

GOERNER,M., HORN,P.A., PETERSON,L., KURRE,P., STORB,R., RASKO,J.E. & KIEM,H.P. (2001). Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. *Blood* **98**, 2065-2070.

HANAZONO,Y., BROWN,K.E., HANDA,A., METZGER,M.E., HEIM,D., KURTZMAN,G.J., DONAHUE,R.E. & DUNBAR,C.E. (1999). In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. *Blood* **94**, 2263-2270.

HANAZONO,Y., NAGASHIMA,T., TAKATOKU,M., SHIBATA,H., AGEYAMA,N., ASANO,T., UEDA,Y., DUNBAR,C.E., KUME,A., TERAO,K., HASEGAWA,M. & OZAWA,K. (2002a). In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model. *Gene Ther* **9**, 1055-1064.

HANAZONO,Y., TERAO,K., SHIBATA,H., NAGASHIMA,T., AGEYAMA,N., ASANO,T., UEDA,Y., KATO,I., KUME,A., HASEGAWA,M. & OZAWA,K. (2002b). Introduction of the green fluorescent protein gene into hematopoietic stem cells results in prolonged discrepancy of in vivo transduction levels between bone marrow progenitors and peripheral blood cells in nonhuman primates. *J Gene Med* **4**, 470-477.

HEIM,D.A., HANAZONO,Y., GIRI,N., WU,T., CHILDS,R., SELLERS,S.E., MUUL,L., AGRICOLA,B.A., METZGER,M., DONAHUE,R.E., TISDALE,J.F. & DUNBAR,C.E. (2000). Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. *Mol. Ther.* **1**, 533-544.

HEMATTI,P., SELLERS,S.E., AGRICOLA,B.A., METZGER,M.E., DONAHUE,R.E. & DUNBAR,C.E. (2003) Retroviral transduction efficiency of rhesus macaque G-CSF-SCF mobilized CD34+ blood cells is superior to G-CSF alone or G-CSF-flt3L mobilized cells. *Blood* (in press)

HORN,P.A., MORRIS,J.C., BUKOVSKY,A.A., ANDREWS,R.G., NALDINI,L., KURRE,P. & KIEM,H.P. (2002a). Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. *Gene Ther.* **9**, 1464-1471.

HORN,P.A., NEFF,T., PETERSON,L.J., MORRIS,J.C., THOMASSON,B.M., SANDEMAIER,B.M. & KIEM,H.-P. (2002b) Efficient lentiviral gene transfer to canine hematopoietic repopulating cells using an overnight transduction protocol. *Blood* **100**, 687a. (Abstract)

HUHN,R.D., TISDALE,J.F., AGRICOLA,B., METZGER,M.E., DONAHUE,R.E. & DUNBAR,C.E. (1999). Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. *Hum. Gene Ther.* **10**, 1783-1790.

IERINO,F.L., GOJO,S., BANERJEE,P.T., GIOVINO,M., XU,Y., GERE,J., KAYNOR,C., AWWAD,M., MONROY,R., REMBERT,J., HATCH,T., FOLEY,A., KOZLOWSKI,T., YAMADA,K., NEETHLING,F.A., FISHMAN,J., BAILIN,M., SPITZER,T.R., COOPER,D.K.C., COSIMI,A.B., LEGUERN,C. & SACHS,D.H. (1999). Transfer of swine major histocompatibility complex class II genes into autologous bone marrow cells of baboons for the induction of tolerance across xenogeneic barriers. *Transplantation* **67**, 1119-1128.

JOSEPHSON,N.C., SABO,K.M. & ABKOWITZ,J.L. (2000). Transduction of feline hematopoietic cells by oncoretroviral vectors pseudotyped with the subgroup A feline leukemia virus (FeLV-A). *Mol. Ther.* **2**, 56-62.

KANTOFF,P.W., FLAKE,A.W., EGLITIS,M.A., SCHARF,S., BOND,S., GILBOA,E., ERLICH,H.,

HARRISON,M.R., ZANJANI,E.D. & ANDERSON,W.F. (1989). In utero gene transfer and expression: a sheep transplantation model. *Blood* **73**, 1066-1073.

KANTOFF,P.W., GILLIO,A.P., MCLACHLIN,J.R., BORDIGNON,C., EGLITIS,M.A., KERNAN,N.A., MOEN,R.C., KOHN,D.B., YU,S.F., KARSON,E., KARLSSON,S., ZWEIBEL,J., GILBOA,E., BLAESE,R.M., NEINHUIS,A., O'REILLY,R.J. & ANDERSON,W.F. (1987). Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. *J. Exp. Med.* **166**, 219-234.

KAPTEIN,L.C.M., VAN BEUSECHEM,V.W. , RIVIERE,I., MULLIGAN,R.C. & VALERIO,D. (1997). Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. *Hum. Gene Ther.* **8**, 1605-1610.

KELLY,P.F., DONAHUE,R.E., VANDERGRIF, J.A., TAKATOKU,M., BONIFACINO,A.C., AGRICOLA,B.A., METZGER,M.E., DUNBAR,C.E. & NIENHUIS,A.W. (2002) Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34-positive cells marked with a RD114 pseudotyped oncoretroviral vector. *Blood Cells Mol.Dis.* (in press)

KIEM,H.P., ANDREWS,R.G., MORRIS,J., PETERSON,L., HEYWARD,S., ALLEN,J.M., RASKO,J.E.J., POTTER,J. & MILLER,A.D. (1998). Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. *Blood* **92**, 1878-1886.

KIEM,H.P., HEYWARD,S., WINKLER,A., POTTER,J., ALLEN,J.M., MILLER,A.D. & ANDREWS,R.G. (1997). Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. *Blood* **90**, 4638-4645.

KIEM,H.P., MCSWEENEY,P.A., BRUNO,B., GOERNER,M., BURON,G., MORRIS,J., STORB,R. & MILLER,A.D. (1999). Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector. *Gene Ther.* **6**, 966-972.

KIEM,H.P., RASKO,J.E., MORRIS,J., PETERSON,L., KURRE,P. & ANDREWS,R.G. (2002). Ex vivo selection for oncoretrovirally transduced green fluorescent protein-expressing CD34-enriched cells increases short-term engraftment of transduced cells in baboons. *Hum. Gene Ther* **13**, 891-899.

KIM,H.J., TISDALE,J.F., WU,T., TAKATOKU,M., SELLERS,S.E., ZICKLER,P., METZGER,M.E., AGRICOLA,B.A., MALLEY,J.D., KATO,I., DONAHUE,R.E. , BROWN,K.E. & DUNBAR,C.E. (2000). Many multi-potential gene-marked progenitor or stem cell clones contribute to hematopoiesis in non-human primates. *Blood* **96**, 1-8.

KLUGE,K.A., BONIFACINO,A.C., SELLERS,S., AGRICOLA,B.A., DONAHUE,R.E. & DUNBAR,C.E. (2002). Retroviral Transduction and Engraftment Ability of Primate Hematopoietic Progenitor and Stem Cells Transduced Under Serum-Free versus Serum-Containing Conditions. *Mol. Ther.* **5**, 316-322.

KURRE,P., MORRIS,J., ANDREWS,R.G., KOHN,D.B. & KIEM,H.P. (2002). Kinetics of Fluorescence Expression in Nonhuman Primates Transplanted with GFP Retrovirus-Modified CD34 Cells. *Mol Ther* **6**, 83-90.

KURRE,P., MORRIS,J., HORN,P.A., HARKEY,M.A., ANDREWS,R.G. & KIEM,H.P. (2001). Gene transfer into baboon repopulating cells: A comparison of Flt-3 Ligand and megakaryocyte growth and development factor versus IL-3 during ex vivo transduction. *Mol Ther* **3**, 920-927.

LICHT,T., HASKINS,M., HENTHORN,P., KLEIMAN,S.E., BODINE,D.M., WHITWAM,T., PUCK,J.M., GOTTESMAN,M.M. & MELNICZEK,J.R. (2002). Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. *Proc. Natl. Acad. Sci. U. S. A* **99**, 3123-3128.

LOTHROP,C.D., Jr., AL LEBBAN,Z.S., NIEMEYER,G.P., JONES,J.B., PETERSON,M.G., SMITH,J.R., BAKER,H.J., MORGAN,R.A., EGLITIS,M.A. & ANDERSON,W.F. (1991). Expression of a foreign gene in cats reconstituted with retroviral vector infected autologous bone marrow. *Blood* **78**, 237-245.

LUCAS,M.L., SEIDEL,N.E., PORADA,C.D., ANDERSON,S.M., MALECH,H.L., QUIGLEY,J.Q., ABKOWITZ,J.L., ZANJANI,E.D. & BODINE,D.M. (2002) Increased transduction of human HSC with retroviruses pseudotyped with FeLV or RD114 envelopes in a sheep/human chimeric model. *Blood* **100**, 678a. (Abstract)

LUTZKO,C., KRUTH,S., ABRAMS-OGG,A.C.G., LAU,K., LI,L., CLARK,B.R., RUEDY,C., NANJI,S., FOSTER,R., KOHN,D., SHULL,R. & DUBÉ,I.D. (1999a). Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine  $\alpha$ -L-iduronidase deficiency. *Blood* **93**, 1895-1905.

LUTZKO,C., OMORI,F., ABRAMS-OGG,A.C., SHULL,R., LI,L., LAU,K., RUEDY,C., NANJI,S., GARTLEY,C., DOBSON,H., FOSTER,R., KRUTH,S. & DUBE,I.D. (1999b). Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. *Hum. Gene Ther.* **10**, 1521-1532.

MEERTENS,L., ZHAO,Y., ROSIC-KABLAR,S., LI,L., CHAN,K., DOBSON,H., GARTLEY,C., LUTZKO,C., HOPWOOD,J., KOHN,D., KRUTH,S., HOUGH,M.R. & DUBE,I.D. (2002). In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. *Hum. Gene Ther.* **13**, 1809-1820.

NEFF,T., HORN,P.A., VALLI,V.E., GOWN,A.M., WARDWELL,S., WOOD,B.L., VON KALLE,C., SCHMIDT,M., PETERSON,L.J., MORRIS,J.C., RICHARD,R.E., CLACKSON,T., KIEM,H.P. & BLAU,C.A. (2002). Pharmacologically regulated in vivo selection in a large animal. *Blood* **100**, 2026-2031.

NELSON,D.M., METZGER,M.E., DONAHUE,R.E. & MORGAN,R.A. (1997). In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning. *Hum. Gene Ther.* **8**, 747-754.

OMORI,F., LUTZKO,C., ABRAMS-OGG,A., LAU,K., GARTLEY,C., DOBSON,H., NANJI,S., RUEDY,C., SINGARAJA,R., LI,L., STEWART,A.K., KRUTH,S. & DUBE,I.D. (1999). Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses. *Exp. Hematol.* **27**, 242-249.

PONDER,K.P., MELNICZEK,J.R., XU,L., WEIL,M.A., O'MALLEY,T.M., O'DONNELL,P.A., KNOX,V.W., AGUIRRE,G.D., MAZRIER,H., ELLINWOOD,N.M., SLEEPER,M., MAGUIRE,A.M., VOLK,S.W., MANGO,R.L., ZWEIGLE,J., WOLFE,J.H. & HASKINS,M.E. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. *Proc. Natl. Acad. Sci. U. S. A* **99**, 13102-13107.

PORADA,C.D., TRAN,N.D., ALMEIDA-PORADA,G., GLIMP,H.A., PIXLEY,J.S., ZHAO,Y., ANDERSON,W.F. & ZANJANI,E.D. (2002). Transduction of long-term-engrafting human hematopoietic stem cells by retroviral vectors. *Hum. Gene Ther.* **13**, 867-879.

ROSENZWEIG,M., CONNOLE,M., GLICKMAN,R., YUE,S.P., NOREN,B., DEMARIA,M. & JOHNSON,R.P. (2001). Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. *Blood* **97**, 1951-1959.

ROSENZWEIG,M., MACVITTIE,T.J., HARPER,D., HEMPEL,D., GLICKMAN,R.L., JOHNSON,R.P., FARESE,A.M., WHITING-THEOBALD,N., LINTON,G.F., YAMASAKI,G., JORDAN,C.T. & MALECH,H.L. (1999). Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. *Blood* **94**, 2271-2286.

SCHMIDT,M., ZICKLER,P., HOFFMANN,G., HAAS,S., WISSLER,M., MUESSIG,A., TISDALE,J.F., KURAMOTO,K., ANDREWS,R.G., WU,T., KIEM,H.P., DUNBAR,C.E. & VON KALLE,C. (2002). Polyclonal long-term repopulating stem cell clones in a primate model. *Blood* **100**, 2737-2743.

SCHUENING,F.G., KAWAHARA,K., MILLER,A.D., TO,R., GOEHLE,S., STEWART,D., MULLALLY,K., FISHER,L., GRAHAM,T.C., APPELBAUM,F.R., HACKMAN,R., OSBORNE,W.R.A. & STORB,R. (1991). Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs. *Blood* **78**, 2568-2576.

SELLERS,S.E., TISDALE,J.F., AGRICOLA,B.A., METZGER,M.E., DONAHUE,R.E., DUNBAR,C.E. & SORRENTINO,B.P. (2001). The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. *Blood* **97**, 1888-1891.

SHI,P.A., DE ANGIOLETTI,M., DONAHUE,R.E., NOTARO,R., LUZZATO,L. & DUNBAR,C.E. (2001) Comparison in the rhesus monkey model of in vivo gene marking with amphotropic and VSV-G pseudotyped retroviral vectors. *Blood* **98**, 871S. (Abstract)

SONNTAG,K.C., EMERY,D.W., YASUMOTO,A., HALLER,G., GERMANA,S., SABLINSKI,T., SHIMIZU,A., YAMADA,K., SHIMADA,H., ARN,S., SACHS,D.H. & LEGUERN,C. (2001). Tolerance to solid organ transplants through transfer of MHC class II genes. *J Clin Invest* **107**, 65-71.

TAKATOKU,M., SELLERS,S., AGRICOLA,B.A., METZGER,M.E., KATO,I., DONAHUE,R.E. & DUNBAR,C.E. (2001). Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. *J. Clin. Invest* **108**, 447-455.

TING,S.S., HARTNETT,B.J., LINTON,G.F., MALECH,H.L. & FELSBURG,P.J. (2002) Gene therapy in canine X-linked severe combined immunodeficiency by RD114 pseudotyped oncoretroviral vector. *Blood* **100**, 427a. (Abstract)

TISDALE,J.F., HANAZONO,Y., SELLERS,S.E., AGRICOLA,B.A., METZGER,M.E., DONAHUE,R.E. & DUNBAR,C.E. (1998). Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. *Blood* **92**, 1131-1141.

TRAN,N.D., PORADA,C.D., ALMEIDA-PORADA,G., GLIMP,H.A., ANDERSON,W.F. & ZANJANI,E.D. (2001). Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. *Blood* **97**, 3417-3423.

TSAI,E.J., MALECH,H.L., KIRBY,M.R., HSU,A.P., SEIDEL,N.E., PORADA,C.D., ZANJANI,E.D., BODINE,D.M. & PUCK,J.M. (2002). Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras. *Blood* **100**, 72-79.

VAN BEUSECHEM,V.W., BAKX,T.A., KAPTEIN,L.C., BART-BAUMEISTER,J.A., KUKLER,A., BRAAKMAN,E. & VALERIO,D. (1993). Retrovirus-mediated gene transfer into rhesus monkey hematopoietic stem cells: the effect of viral titers on transduction efficiency. *Hum. Gene Ther.* **4**, 239-247.

VAN BEUSECHEM,V.W., BART-BAUMEISTER,J.A., BAKX,T.A., KAPTEIN,L.C., LEVINSKY,R.J. & VALERIO,D. (1994). Gene transfer into nonhuman primate CD34+CD11b- bone marrow progenitor cells capable of repopulating lymphoid and myeloid lineages. *Hum. Gene Ther.* **5**, 295-305.

VAN BEUSECHEM,V.W., BART-BAUMEISTER,J.A., HOOGERBRUGGE,P.M. & VALERIO,D. (1995). Influence of interleukin-3, interleukin-6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo. *Gene Ther.* **2**, 245-255.

VAN BEUSECHEM,V.W., KUKLER,A., HEIDT,P.J. & VALERIO,D. (1992). Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. *Proc. Natl. Acad. Sci. U. S. A.* **89**, 7640-7644.

VANIN,E.F., KALOSS,M., BROCIUS,C. & NIENHUIS,A.W. (1994). Characterization of replication-competent retrovirus from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. *J. Virol.* **68**, 4241-4250.

WHITWAM,T., HASKINS,M.E., HENTHORN,P.S., KRASZEWSKI,J.N., KLEIMAN,S.E., SEIDEL,N.E., BODINE,D.M. & PUCK,J.M. (1998). Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes. *Blood* **92**, 1565-1575.

WU,T., KIM,H.J., SELLERS,S.E., MEADE,K.E., AGRICOLA,B.A., METZGER,M.E., KATO,I., DONAHUE,R.E., DUNBAR,C.E. & TISDALE,J.F. (2000). Prolonged high-level detection of retrovirally-marked hematopoietic cells in non-human primates after transduction of CD34+ progenitors using clinically feasible methods. *Mol. Ther.* **1**, 285-293.

XU,L., HASKINS,M.E., MELNICZEK,J.R., GAO,C., WEIL,M.A., O'MALLEY,T.M., O'DONNELL,P.A., MAZRIER,H., ELLINWOOD,N.M., ZWEIGLE,J., WOLFE,J.H. & PONDER,K.P. (2002). Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. *Mol. Ther.* **5**, 141-153.

XU,L.C., KARLSSON,S., BYRNE,E.R., KLUEPFEL-STAHLS,S., KESSLER,S.W., AGRICOLA,B.A., SELLER,S., KIRBY,M., DUNBAR,C.E., BRADY,R.O., NIENHUIS,A.W. & DONAHUE,R.E. (1995). Long-term in vivo expression of the human glucocerebrosidase gene in non-human primates using retroviral supernatant transduction protocols. *Proc. Natl. Acad. Sci. U. S. A.* **92**, 4372-4376.